Medium-chain Fatty Acids Improve Cognitive Function in Intensively Treated Type 1 Diabetic Patients and Support in Vitro Synaptic Transmission During Acute Hypoglycemia
Overview
Authors
Affiliations
Objective: We examined whether ingestion of medium-chain triglycerides could improve cognition during hypoglycemia in subjects with intensively treated type 1 diabetes and assessed potential underlying mechanisms by testing the effect of beta-hydroxybutyrate and octanoate on rat hippocampal synaptic transmission during exposure to low glucose.
Research Design And Methods: A total of 11 intensively treated type 1 diabetic subjects participated in stepped hyperinsulinemic- (2 mU x kg(-1) x min(-1)) euglycemic- (glucose approximately 5.5 mmol/l) hypoglycemic (glucose approximately 2.8 mmol/l) clamp studies. During two separate sessions, they randomly received either medium-chain triglycerides or placebo drinks and performed a battery of cognitive tests. In vitro rat hippocampal slice preparations were used to assess the ability of beta-hydroxybutyrate and octanoate to support neuronal activity when glucose levels are reduced.
Results: Hypoglycemia impaired cognitive performance in tests of verbal memory, digit symbol coding, digit span backwards, and map searching. Ingestion of medium-chain triglycerides reversed these effects. Medium-chain triglycerides also produced higher free fatty acids and beta-hydroxybutyrate levels compared with placebo. However, the increase in catecholamines and symptoms during hypoglycemia was not altered. In hippocampal slices beta-hydroxybutyrate supported synaptic transmission under low-glucose conditions, whereas octanoate could not. Nevertheless, octanoate improved the rate of recovery of synaptic function upon restoration of control glucose concentrations.
Conclusions: Medium-chain triglyceride ingestion improves cognition without adversely affecting adrenergic or symptomatic responses to hypoglycemia in intensively treated type 1 diabetic subjects. Medium-chain triglycerides offer the therapeutic advantage of preserving brain function under hypoglycemic conditions without causing deleterious hyperglycemia.
Ferraz L, Barros M, Almeida K, Silva M, Bueno N Braz J Med Biol Res. 2024; 57:e13649.
PMID: 39194033 PMC: 11349153. DOI: 10.1590/1414-431X2024e13649.
Buchholz A, Deme P, Betz J, Brandt J, Haughey N, Cervenka M Front Endocrinol (Lausanne). 2024; 15:1182519.
PMID: 38505743 PMC: 10949529. DOI: 10.3389/fendo.2024.1182519.
Al-Naqeb G, Kalmpourtzidou A, De Giuseppe R, Cena H Nutrients. 2023; 15(22).
PMID: 38004221 PMC: 10674509. DOI: 10.3390/nu15224827.
GPR84-mediated signal transduction affects metabolic function by promoting brown adipocyte activity.
Sun X, An Y, Paschoal V, de Souza C, Wang M, Vishvanath L J Clin Invest. 2023; 133(24).
PMID: 37856216 PMC: 10721148. DOI: 10.1172/JCI168992.
Kojima K, Ishikawa H, Watanabe S, Nosaka N, Mutoh T Nutrients. 2023; 15(14).
PMID: 37513691 PMC: 10383836. DOI: 10.3390/nu15143275.